1. |
Benjamin EJ, Wolf PA, D'Agostino RB, et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation, 1998, 98(10): 946-952.
|
2. |
Diker E, Aydogdu S, Ozdemir M, et al. Prevalence and predictors of atrial fibrillation in rheumatic valvular heart disease. Am J Cardiol, 1996, 77(1): 96-98.
|
3. |
Cardin S, Libby E, Pelletier P, et al. Contrasting gene expression profiles in two canine models of atrial fibrillation. Circ Res, 2007, 100(3): 425-433.
|
4. |
Everett TH 4th, Li H, Mangrum JM, et al. Electrical, morphological, and ultrastructural remodeling and reverse remodeling in a canine model of chronic atrial fibrillation. Circulation, 2000, 102(12): 1454-1460.
|
5. |
Li D, Shinagawa K, Pang L, et al. Effects of angiotensin eonveing enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation, 2001, 104(21): 2608-2614.
|
6. |
Nazir SA, Lab MJ. Mechanoelectric feedback in the atrium of the isolated guinea-pig heart. Cardiovasc Res, 1996, 32(1): 112-119.
|
7. |
Tsai CT, Lai LP, Kuo KT, et al. Angiotensin Ⅱ activates signal transducer and activators of transcription 3 via Rac1 in atrial myocytes and fibroblasts: implication for the therapeutic effect of statin in atrial structural remodeling. Circulation, 2008, 117(3): 344-355.
|
8. |
Spach MS. Mounting evidence that fibrosis generates a major mechanism for atrial fibrillation. Circ Res, 2007, 101(8): 743-745.
|
9. |
Ehrlich JR, Hohnloser SH, Nattel S. Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence. Eur Heart J, 2006, 27(5): 512-518.
|
10. |
Dostal DE, Hunt RA, Kule CE, et al. Molecular mechanisms of angiotensin Ⅱ in modulating cardiac function: intracardiac effects and signal transduction pathways. J Mol Cell Cardiol, 1997, 29(11): 2893-2902.
|
11. |
Sugden PH, Clerk A. Regulation of the ERK subgroup of MAP kinase cascades through G protein-coupled receptors. Cell Signal, 1997, 9(5): 337-351.
|
12. |
Ushio-Fukai M, Alexander RW, Akers M, et al. p38 Mitogen-activated protein kinase is a critical component of the redox-sensitive signaling pathways activated by angiotensin Ⅱ. Role in vascular smooth muscle cell hypertrophy. J Biol Chem, 1998, 273(24): 15022-15029.
|
13. |
Zou Y, Komuro I, Yamazaki T, et al. Cell type-specific angiotensin Ⅱ-evoked signal transduction pathways: critical roles of Gbetagamma subunit, Src family, and Ras in cardiac fibroblasts. Circ Res, 1998, 82(3): 337-345.
|
14. |
Adam O, Lavall D, Theobald K, et al. Rac1-induced connective tissue growth factor regulates connexin 43 and N-cadherin expression in atrial fibrillation. J Am Coll Cardiol, 2010, 55(5): 469-480.
|
15. |
Abo A, Pick E, Hall A, et al. Activation of the NADPH oxidase involves the small GTP-binding protein p21rac1. Nature, 1991, 353(6345): 668-670.
|
16. |
Adam O, Frost G, Custodis F, et al. Role of Rac1 GTPase activation in atrial fibrillation. J Am Coll Cardiol, 2007, 50(4): 359-367.
|
17. |
Dudley SC Jr, Hoch NE, McCann LA, et al. Atrial fibrillation increases production of superoxide by the left atrium and left atrial appendage: role of the NADPH and xanthine oxidases. Circulation, 2005, 112(9): 1266-1273.
|
18. |
Takemoto M, Node K, Nakagami H, et al. Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J Clin Invest, 2001, 108(10): 1429-1437.
|
19. |
Adam O, Neuberger HR, Böhm M, et al. Prevention of atrial fibrillation with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Circulation, 2008, 118(12): 1285-1293.
|
20. |
McGaffin KR, Zou B, McTiernan CF, et al. Leptin attenuates cardiac apoptosis after chronic ischaemic injury. Cardiovasc Res, 2009, 83(2): 313-324.
|
21. |
Paradis P, Dali-Youcef N, Paradis FW, et al. Overexpression of angiotensin Ⅱ type Ⅰ receptor in cardiomyocytes induces cardiac hypertrophy and remodeling. Proc Natl Acad Sci U S A, 2000, 97(2): 931-936.
|
22. |
Yue H, Li W, Desnoyer R, et al. Role of nuclear unphosphorylated STAT3 in angiotensin Ⅱ type 1 receptor-induced cardiac hypertrophy. Cardiovasc Res, 2010, 85(1): 90-99.
|